Valuation: Absci Corporation

Market Cap 1.3B 1.18B 1.09B 990M 1.86B 120B 1.95B 13.25B 5.27B 65.62B 4.87B 4.76B 206B P/E 2026 *
-9.47x
P/E 2027 * -9.93x
Enterprise Value 1.09B 990M 912M 829M 1.56B 101B 1.64B 11.1B 4.41B 54.95B 4.08B 3.99B 172B EV / Sales 2026 *
487x
EV / Sales 2027 * 278x
Free-Float
88.3%
Yield 2026 *
-
Yield 2027 * -
1 day-7.97%
1 week-11.12%
Current month-32.52%
1 month-25.20%
3 months-21.36%
6 months+47.54%
Current year+115.19%
1 week 7.29
Extreme 7.29
8.73
1 month 7.29
Extreme 7.29
12.54
Current year 2.24
Extreme 2.24
12.54
1 year 2.24
Extreme 2.24
12.54
3 years 1.35
Extreme 1.35
12.54
5 years 1.11
Extreme 1.1111
12.54
10 years 1.11
Extreme 1.1111
31.53
Manager TitleAgeSince
Chief Executive Officer 36 01/08/2011
Director of Finance/CFO 53 31/08/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 36 01/01/2011
Director/Board Member 59 01/08/2020
Director/Board Member 57 07/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
29/10/26 Tax

Chief Executive Officer

-79,860 0.0465%
12/10/26 Tax

Controller/Auditor

-22,325 0.0130%
12/10/26 Tax

Chief Financial Officer

-387 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-7.97%-11.12%+156.31%+452.21% 1.3B
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -2.03%-2.21%+45.39%+207.71% 40B
Weighted average by Cap. -1.50%-1.88%+32.23%+156.11%

Financials

2026 *2027 *
Net sales 2.23M 2.03M 1.87M 1.7M 3.2M 207M 3.36M 22.8M 9.06M 113M 8.38M 8.2M 354M 4.43M 4.04M 3.72M 3.38M 6.35M 410M 6.67M 45.26M 17.99M 224M 16.62M 16.27M 703M
Net income -130M -119M -109M -99.52M -187M -12.07B -196M -1.33B -529M -6.59B -489M -479M -20.69B -137M -125M -115M -105M -196M -12.68B -206M -1.4B -556M -6.92B -514M -503M -21.73B
Net Debt -211M -192M -177M -161M -302M -19.53B -317M -2.15B -856M -10.66B -791M -774M -33.47B -66.14M -60.24M -55.51M -50.49M -94.72M -6.12B -99.55M -676M -269M -3.35B -248M -243M -10.5B
Projected Income Statement - Annual - Absci Corporation
Logo Absci Corporation
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Employees
140
Date Price Change Volume
20/11/26 $7.510 -7.97% 4,747,472
19/11/26 $8.160 -0.24% 5,083,731
18/11/26 $8.180 +7.92% 5,667,576
17/11/26 $7.580 +1.40% 4,699,470
16/11/26 $7.475 -11.54% 7,872,202
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Absci Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
7.510USD
Average target price
15.09USD
Spread / Average Target
+100.94%
  1. Stock Market
  2. Stocks
  3. ABSI Stock